Nanobiotix S.A. American Depositary Shares (NBTX)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the 2026-10-13 close of $21.49, the market values Nanobiotix at $1.6B. That is a heavy price for a clinical-stage biotech with a negative FairStock P/E calculation of -16.92 and a ROCE of -21.34%. The Piotroski F-Score of 1/9 and FairStock score of 20/100 tell me the financial statements are not showing the improving fundamentals I look for. The Altman Z-Score of 6.10 is a relative bright spot, suggesting the balance sheet may not be under immediate distress on that measure, but D/E is N/A, so I cannot fully judge leverage. The company has 98 employees and is developing NBTXR3 for multiple cancers, with a partnership with Lian Oncology. The potential is real, but potential is not a moat. I see no revenue growth or profit growth data, no dividend, and no Lynch category because there are only 0 years of filed results where 3 are needed. That means I cannot classify it as a consistent grower or value it from a multi-year earnings record. The 52-week range of $14.78 to $57.14 shows how violently Mr. Market can price this story. Graham would ask for a margin of safety in numbers; here the numbers are losses and missing history. Buffett would ask for a durable competitive advantage and predictable cash earnings; here both are unproven. I would call it a speculative research bet, not a conservative investment. The price reflects hope for clinical and commercial success, and hope alone does not protect capital.

In plain English: Nanobiotix S.A. American Depositary Shares is a small healthcare company working on a cancer treatment called NBTXR3. The business looks weak today because it is not profitable and the available financial scores are poor. At $21.49, the price looks expensive compared with the lack of earnings, so its value depends heavily on future development success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer